DALLAS, February 13, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Dementia - Pipeline Review, H1 2015" to its store. This report provides an overview of the Dementia's therapeutic pipeline and key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.
The report "Dementia - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.features on late-stage and discontinued projects.
Dementia is not a particular disease. Dementia is a slow decline of mental capability that affects cerebral and social skills to the point where daily life becomes complicated. Alzheimer's disease is the best known and most common disorder under the umbrella of dementia. Vascular dementia is the second most common cause of dementia caused by brain damage from cerebrovascular. Dementia may be caused by a number of factors, such as alcoholism, brain injury, drug abuse, side effects to certain medications, thyroid function abnormalities, vitamin B12 deficiency.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269518 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Dementia - Pipeline Review, H1 2015 report include Actinogen Limited, Alector LLC, AlzProtect SAS, BioArctic Neuroscience AB, Biogen Idec Inc., Biotie Therapies Corp., Bristol-Myers Squibb Company, Chase Pharmaceuticals Corporation, Chronos Therapeutics Limited, Daewoong Pharmaceutical Co., Ltd., Echo Pharmaceuticals B.V., Eisai Co., Ltd., FORUM Pharmaceuticals Inc., Hyundai Pharmaceutical Co., Ltd., Ildong Pharmaceutical Co., Ltd., IMMD Inc., ImStar Therapeutics Inc., Integrative Research Laboratories Sweden AB, Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., Neurimmune Holding AG, Oryzon Genomics S.A., Otsuka Holdings Co., Ltd., Pacific Northwest Biotechnology, LLC, ProteoTech, Inc., SK Chemicals Co., Ltd., Stelic Institute & Co., Sumitomo Dainippon Pharma Co., Ltd., Sylentis S.A., TauRx Therapeutics Ltd., Tautatis Incorporated, Varinel, Inc., WhanIn Pharmaceutical Co., Ltd.
Drugs profile discussed in this report include Antisense Oligonucleotide to Inhibit microRNA for Neurology, aripiprazole, AVCRI-104P3, AZP-2006, brexpiprazole, choline alfoscerate SR, CPC-201, CPC-252, dehydroevodiamine hydrochloride, dronabinol, Drugs for Dementia, Drugs to Agonize c-MET for Dementia, Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment, DWJ-1365, E-2609, encenicline hydrochloride, FRM-0334, GIBH-130, gugulipid, IIPP-1, IMD-4482, IPN-007, IRL-752, ITI-007, KR-12, NAT, NI-205, NI-308, NNC-269100, OG-635, PD-0805, PD-61W3, PD-61W3 Backup, PST-900, RDC-5, SID-111, SYN-120, TAK-070, TauC-3, TPI-287, TRx-0237, TTT-3002, UE-2343, VAR-10100, WIB-1001C and zonisamide.
Scope of Dementia - Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Dementia; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type; Latest news and deals relating related to pipeline products
Explore more reports on Neurology Drugs @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/neurology-drugs .
Get more reports on Neurology Drugs:
This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.
Companies discuss in the report include Addex Therapeutics Ltd, Azevan Pharmaceuticals, Inc., Catalyst Pharmaceutical Partners, Inc., Humanetics Corporation, Intra-Cellular Therapies, Inc., Marinus Pharmaceuticals, Inc., Nanotherapeutics, Inc., Neuralstem, Inc., Neurocrine Biosciences, Inc., NeuroNascent, Inc., Omeros Corporation, Otsuka Holdings Co., Ltd., Polleo Pharma Limited, Tonix Pharmaceuticals Holding Corp., Vanda Pharmaceuticals Inc.
There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Eisai's Aricept (donepezil hydrochloride) is a piperidine derivative that acts centrally as a reversible AChEI. Aricept is approved at the strengths of 5, 10, and 23mg and is indicated for the treatment of mild to severe Alzheimer's dementia. As a member of the AChEI class, donepezil can only provide symptomatic relief and cannot modify the underlying disease progression.
Exelon (rivastigmine, rivastigmine tartrate), which is manufactured and marketed by Novartis, is a reversible ChEI indicated for the treatment of mild to moderate dementia of the Alzheimer's type. The exact mechanism of action (MOA) of rivastigmine is unknown, but it is thought to increase ACh concentrations through reversible inhibition of AChE by hydrolysis.
RnRMarketResearch.com is a database of selected syndicated market reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research